Comparative Pharmacology
Head-to-head clinical analysis: AMPICILLIN TRIHYDRATE versus LAROTID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMPICILLIN TRIHYDRATE versus LAROTID.
AMPICILLIN TRIHYDRATE vs LAROTID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and autolysin activity.
Larotrectinib is a selective inhibitor of tropomyosin receptor kinase (TRK) A, B, and C. It inhibits TRK kinase activity by binding to the ATP-binding site, leading to inhibition of downstream signaling pathways, which results in reduced cell proliferation and tumor growth in tumors with NTRK gene fusions.
250-500 mg PO q6h or 1-2 g IV/IM q4-6h; up to 12 g/day IV for severe infections.
Larotrectinib 100 mg orally twice daily, with or without food, for adult patients.
None Documented
None Documented
Terminal elimination half-life 1-1.8 hours; prolonged in renal impairment (up to 10-20 hours in anuria)
30 minutes; prolonged in renal impairment (up to 20 hours in anuria).
Renal: 75-90% unchanged; biliary: small amount; fecal: negligible
Renal: 70-80% unchanged by glomerular filtration and tubular secretion; Biliary/Fecal: <10% as inactive metabolites.
Category A/B
Category C
Penicillin Antibiotic
Penicillin Antibiotic